ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma Meeting Abstract

  

Authors:	Lacuna, K. P.; Lee, S. M.; Ge, L.; Druta, M.; Conley, A. P.; Keohan, M. L.; Agulnik, M.; Burgess, M. A.; Chalmers, A. W.; D'Amato, G. Z.; Powers, B.; Seetharam, M.; Siontis, B. L.; Weiss, M. C.; Bose, S.; Sheikh, T.; Piekarz, R.; Schwartz, G. K.; Ingham, M.
Abstract Title:	ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.11531
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164013133&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting abstract: 11531 -- Meeting also presented virtually -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209569